secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0001193125-23-076278
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences reports Q4 2022 net loss $43.7M; cash runway into 2025 on $170M GSK upfront
--------------------------------------------------------------------------------

- Q4 2022 net loss $43.7M vs $34.8M in Q4 2021; full-year 2022 net loss $161.8M vs $122.2M in 2021.
- Cash and equivalents $88.5M at Dec 31, 2022; after period-end, received $170M upfront from GSK collaboration.
- GSK collaboration includes up to $3.3B in potential milestones; Wave licensed WVE-006 for AATD to GSK.
- WVE-006 on track for CTA submission in 2H 2023; Part B of WVE-N531 DMD study to begin in 2023 with dystrophin data in 2024.
- Single-dose data from WVE-003 (HD) and WVE-004 (ALS/FTD) expected in 1H 2023; Takeda option for 50:50 co-development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312523076278/0001193125-23-076278-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312523076278/d451722d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-076278

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer